Zobrazeno 1 - 10 of 116 pro vyhledávání: '"Verina D"'
1
Akademický článek
Regression of smoldering myeloma with treatment of Gaucher disease.
Autor: Barley K; Department of Geriatrics and Palliative Care, Icahn School of Medicine at Mount Sinai, New York, NY., Parekh A; Ardsley High School, Ardsley, NY.; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Salam S; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY., Mendu DR; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY., Shukla RP; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Vatti D; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.; Department of Biology, New York University, New York, NY., Verina D; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Stauffer C; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY., Salib C; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY., El Jamal S; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY., Teruya-Feldstein J; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY., Duffield AS; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY., Leshchenko VV; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Jagannath S; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Balwani M; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY., Parekh S; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY.; Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Publikováno v: Blood advances [Blood Adv] 2024 Apr 09; Vol. 8 (7), pp. 1634-1638.
Zobrazit plný text záznamu
2
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Autor: Elnaggar M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Agte S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Restrepo P; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Ram M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Melnekoff D; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Adamopoulos C; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Stevens MM; Travera, Medford, MA, USA., Kappes K; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Leshchenko V; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Verina D; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Poulikakos PI; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Parekh S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Laganà A; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.
Publikováno v: Journal of hematology & oncology [J Hematol Oncol] 2023 May 08; Vol. 16 (1), pp. 52. Date of Electronic Publication: 2023 May 08.
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Autor: Elnaggar M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Agte S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Restrepo P; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Ram M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Melnekoff D; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Adamopoulos C; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Stevens MM; Travera, Medford, MA, USA., Kappes K; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Leshchenko V; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Verina D; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Poulikakos PI; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Parekh S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Laganà A; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.
Publikováno v: Journal of hematology & oncology [J Hematol Oncol] 2022 Aug 17; Vol. 15 (1), pp. 109. Date of Electronic Publication: 2022 Aug 17.
Zobrazit plný text záznamu
5
Akademický článek
A Focus on Newly Diagnosed Multiple Myeloma.
Autor: Brigle K; VCU Massey Cancer Center, Richmond, Virginia., Verina D; Mount Sinai Medical Center, New York, New York., Faiman B; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
Publikováno v: Journal of the advanced practitioner in oncology [J Adv Pract Oncol] 2022 Jul; Vol. 13 (Suppl 4), pp. 7-14. Date of Electronic Publication: 2022 Jul 28.
Zobrazit plný text záznamu
6
Akademický článek
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
Autor: Sanchez L; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Richter J; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Cho HJ; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Jagannath S; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Madduri D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Parekh S; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Richard S; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Tam L; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Verina D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Chari A; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1185, New York, NY 10029, USA.
Publikováno v: Therapeutic advances in hematology [Ther Adv Hematol] 2021 Jan 22; Vol. 12, pp. 2040620720987075. Date of Electronic Publication: 2021 Jan 22 (Print Publication: 2021).
Zobrazit plný text záznamu
7
Akademický článek
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Autor: Van Oekelen O; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Parekh S; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Cho HJ; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Vishnuvardhan N; Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA., Madduri D; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Richter J; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Ip C; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Lau K; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Florendo E; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Mancia IS; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Thomas J; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Verina D; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Chan E; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Zarychta K; Icahn School of Medicine at Mount Sinai, New York, NY, USA., La L; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Strumolo G; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Melnekoff DT; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Leshchenko VV; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Kim-Schulze S; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Couto S; Celgene Corporation, Translational Development and Diagnostics, Summit, NJ, USA., Wang M; Celgene Corporation, Translational Development and Diagnostics, Summit, NJ, USA., Pierceall WE; Celgene Corporation, Translational Development and Diagnostics, Summit, NJ, USA., Thakurta A; Celgene Corporation, Translational Development and Diagnostics, Summit, NJ, USA., Laganà A; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Jagannath S; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Chari A; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2020 Sep; Vol. 61 (9), pp. 2208-2215. Date of Electronic Publication: 2020 Aug 19.
Zobrazit plný text záznamu
8
Report
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m 2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m 2 .
Autor: Barley K; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Sanchez L; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Cho HJ; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Parekh S; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Madduri D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Richter J; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Isola L; Bone Marrow and Stem Cell Transplant Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Goldstein T; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Dhadwal A; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Zarychta K; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Sanchez GM; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Catamero D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Verina D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Florendo E; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Yum MH; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., La L; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Gullie J; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Chan E; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Jagannath S; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Chari A; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Publikováno v: American journal of hematology [Am J Hematol] 2020 Feb; Vol. 95 (2), pp. E51-E54. Date of Electronic Publication: 2019 Dec 22.
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.
Autor: Curcio, Antonio1 (AUTHOR) antonio.curcio@unicz.it, Rocca, Roberta1,2 (AUTHOR) alcaro@unicz.it, Alcaro, Stefano1,2 (AUTHOR) artese@unicz.it, Artese, Anna1,2 (AUTHOR)
Publikováno v: Pharmaceuticals (14248247). May2024, Vol. 17 Issue 5, p620. 48p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje